On April 13, 2021 Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company, reported its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Harbour BioMed, APR 13, 2021, View Source [SID1234578000]). This meeting is being held virtually from April 10-15, 2021. The anti-B7H7 antibody is a novel immune-oncology antibody with potent anti-tumor activity generated using HBM’s proprietary H2L2 Harbour Mice platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the presentation:
Harbour BioMed’s presentation
By leveraging its innovative discovery engine based on the Harbour Mice antibody platforms, HBM has built a sustained capability to deliver novel antibody therapeutics in the field of oncology and immunology. Following the previously reported monoclonal antibody against a novel target CCR8, HBM now reports another first-in-class therapeutic antibody targeting a novel immune checkpoint – B7H7. B7H7 is mainly expressed in some PD-L1 negative/low tumors and may serve as an alternative immune escape pathway for these tumors. This antibody generated from H2L2 Harbour Mice demonstrates excellent preclinical activity and anti-tumor efficacy.
About B7H7
B7H7 is a novel immune checkpoint of B7 family, which is highly expressed on a variety of human cancers including colon, pancreatic, kidney, breast, bladder, lung cancers, etc. and is associated with metastatic disease and poorer survival rate of these patients. B7H7 antibody may present a novel anti-tumor therapy complementary to PD-L1/PD1 based therapy. B7H7 antibodies show significant T cell activation effect in vitro and tumor growth inhibition in several mouse tumor models.